Irbesartan and hydrochlorothiazide tablets are a widely used fixed-dose combination antihypertensive whose clinical efficacy depends directly on the accurate content of both active pharmaceutical ingredients. Assay (content) testing verifies that every tablet delivers the labeled amounts of irbesartan and hydrochlorothiazide within pharmacopoeial limits, ensuring batch-to-batch consistency, regulatory compliance, and patient safety. This article explains the sample types, testing items, analytical methods, applicable standards, and frequently asked questions related to content determination of this combination product.
Technical Overview
Irbesartan and hydrochlorothiazide tablets combine two complementary antihypertensive agents: irbesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. The combination produces an additive blood-pressure-lowering effect, and commercial strengths typically include 150 mg/12.5 mg, 300 mg/12.5 mg, and 300 mg/25 mg of irbesartan/hydrochlorothiazide, respectively.
Content testing (assay) quantitatively determines the amount of each active pharmaceutical ingredient (API) present in the finished dosage form, expressed as a percentage of the labeled claim. Because hydrochlorothiazide is dosed at low milligram levels and the two actives differ significantly in polarity and UV spectral behavior, the method must be highly specific, sensitive, and stability-indicating. Regulatory expectations, including those of the ICH quality guidelines and national pharmacopoeias, require that the assay of both components be demonstrated simultaneously or by individually validated procedures, with results falling within tightly defined acceptance limits.
Testing Samples
Finished Commercial Products
Tablets collected from routine production batches for release testing, post-market surveillance, or quality verification. Sampling is normally performed according to a statistically justified plan to ensure the sample represents the entire batch.
Registration and Process Validation Batches
Batches manufactured during product development, technology transfer, or process validation, where assay data support the marketing authorization dossier and demonstrate manufacturing consistency.
Stability Study Samples
Tablets stored under ICH long-term, intermediate, and accelerated conditions (for example, 25 °C/60% RH and 40 °C/75% RH), tested at defined time points to monitor content drift and degradation of either active ingredient over the proposed shelf life.
Regulatory, Dispute, and Research Samples
Samples submitted by regulatory authorities, distributors, or customers for quality evaluation, batch dispute resolution, generic-product comparison, or academic and formulation research purposes.
Testing Items
Although the core focus is content determination, a complete evaluation of irbesartan and hydrochlorothiazide tablets typically covers the following items, which may be commissioned individually or as a package at accredited third-party laboratories:
- Assay (content) of irbesartan, reported as a percentage of the labeled amount
- Assay (content) of hydrochlorothiazide, reported as a percentage of the labeled amount
- Identification of both actives by HPLC retention behavior, UV spectra (DAD), or infrared spectroscopy
- Uniformity of dosage units (content uniformity and/or weight variation)
- Dissolution test and dissolution profile of both active ingredients
- Related substances (degradation products and process impurities of each API)
- Water content (Karl Fischer titration) and loss on drying, where applicable
- System suitability and method validation data supporting the reported results
Testing Methods
Primary Method: Reversed-Phase HPLC with UV Detection
The pharmacopoeial and industry-standard approach is reversed-phase high-performance liquid chromatography (HPLC) with UV or diode-array detection. A typical procedure uses a C18 column (for example, 250 mm × 4.6 mm, 5 µm), a mobile phase consisting of a phosphate buffer (often adjusted to an acidic pH with phosphoric acid) and acetonitrile or methanol, and a detection wavelength selected in the range of approximately 220–260 nm (commonly 225 nm) at which both analytes show adequate absorbance. Quantification is performed by external calibration against certified reference standards of irbesartan and hydrochlorothiazide, allowing both components to be determined in a single chromatographic run.
Sample Preparation
A representative number of tablets (commonly 20) is weighed to determine the average tablet weight, then finely powdered. An accurately weighed portion of the powder is extracted with a suitable solvent or diluent by sonication, diluted to volume, centrifuged if necessary, and filtered through a 0.45 µm membrane before injection. Recovery of the extraction step is verified during method validation to demonstrate complete release of both actives from the matrix.
Method Validation
Whichever method is applied—the Chinese Pharmacopoeia (ChP), the United States Pharmacopeia (USP-NF), the European Pharmacopoeia (Ph. Eur.), or an internally developed procedure—it must be validated or verified in accordance with ICH Q2 requirements. Key parameters include:
- Specificity: absence of placebo, excipient, or degradation-product interference
- Linearity: correlation coefficient typically not less than 0.999 over the working range
- Accuracy: recovery generally within 98.0%–102.0% of the theoretical amount
- Precision: repeatability and intermediate precision with RSD commonly not more than 2.0%
- Range, solution stability, robustness, and system suitability (column efficiency, tailing factor, and replicate-injection RSD)
Stability-Indicating Capability
For registration and stability studies, the method should be demonstrated to be stability-indicating through forced degradation experiments (acidic and basic hydrolysis, oxidation, thermal stress, and photolysis), confirming that degradation products do not co-elute with or bias the quantification of either active ingredient.
Acceptance Criteria
Assay results are commonly required to fall within 95.0%–105.0% of the labeled amount for each active ingredient, although the exact limits must follow the applicable pharmacopoeial monograph or the approved registration standard (some dossiers specify 90.0%–110.0%). Results for both irbesartan and hydrochlorothiazide must independently meet the criteria for the batch to be judged conforming.
Applications
Content testing of irbesartan and hydrochlorothiazide tablets supports multiple stages of the pharmaceutical product lifecycle:
- Batch release testing by manufacturers to confirm compliance before distribution
- Generic product development and equivalence studies, including comparison with reference preparations
- Stability programs establishing and monitoring shelf life in accordance with ICH guidelines
- Regulatory submissions, pharmacopoeial compliance verification, and post-market quality surveillance
- Quality investigations, out-of-specification follow-up, and resolution of commercial disputes
- Import testing and market-check programs conducted by or on behalf of regulatory authorities
FAQ
How many tablets are required for the test?
For assay testing alone, approximately 20 tablets are generally sufficient. If content uniformity, dissolution, or related substances are also commissioned, a submission of 60–100 tablets is recommended to cover all sampling and retest requirements.
Can both active ingredients be measured in a single analysis?
Yes. Validated simultaneous HPLC methods quantify irbesartan and hydrochlorothiazide in one chromatographic run, which improves efficiency and reduces sample consumption while maintaining full compliance with validation requirements.
Which standards govern the testing?
Testing is performed against recognized pharmacopoeial standards such as the Chinese Pharmacopoeia (ChP), the United States Pharmacopeia (USP-NF), or the European Pharmacopoeia (Ph. Eur.), supported by ICH method-validation and stability guidelines, or against a client-supplied validated method.
What is the typical turnaround time?
A routine assay of both components usually requires about 5–10 working days, including sample preparation, chromatographic analysis, and reporting. Studies involving full method validation, forced degradation, or stability time-point testing require additional time.
What happens if a result falls outside the specification?
Out-of-specification results trigger a structured investigation covering analytical error, sample handling, and manufacturing review, following recognized quality-management principles, before any conclusion regarding batch quality is drawn.
Is a test report from an accredited laboratory acceptable for regulatory use?
Reports issued by accredited third-party laboratories operating under ISO/IEC 17025 quality systems, containing full method details, standard lot information, chromatographic data, and clear acceptance-criterion comparisons, are widely accepted for regulatory submissions, market surveillance, and commercial verification purposes.